Research programme: hepatitis C virus therapy - Rigel
Latest Information Update: 20 Mar 2009
At a glance
- Originator Rigel Pharmaceuticals
- Mechanism of Action Hepatitis C virus replication inhibitors; Protein synthesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 11 Nov 2005 This programme is still in active development
- 22 Dec 2003 Preclinical trials in Hepatitis C treatment in USA (unspecified route)